From what 0 stock analysts predict, the share price for Medicenna Therapeutics Corp. (MDNAF) might increase by 6.75% in the next year. This is based on a 12-month average estimation for MDNAF. Price targets go from $1.81479 to $1.81479. The majority of stock analysts believe MDNAF is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
MDNAF is a stock in Healthcare which has been forecasted to be worth $1.81479 as an average. On the higher end, the forecast price is $1.81479 USD by from and on the lower end MDNAF is forecasted to be $1.81479 by from .
These are the latest 20 analyst ratings of MDNAF.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Oppenheimer | Outperform | Initiates | Dec 18, 2020 | |
Oppenheimer | Outperform | Initiates | Dec 17, 2020 | |
HC Wainwright & Co. | Buy | Initiates | Sep 10, 2020 |
When did it IPO
2017
Staff Count
16
Country
Canada
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Fahar Merchant Ph.D.
Market Cap
$133.2M
In 2023, MDNAF generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MDNAF's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Updated clinical results from the Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors will be presented soon.
Why It Matters - Updated clinical results may indicate the efficacy and safety of MDNA11, influencing investor sentiment and stock performance for the company involved in cancer treatment.
Summary - Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced the voting results from its annual shareholder meeting held on September 26, 2024.
Why It Matters - Voting results from Medicenna's annual meeting can indicate shareholder confidence and strategic direction, impacting stock performance and market sentiment.
Summary - MDNA209, a first-in-class IL-2 Super-antagonist, is being developed for autoimmune diseases, which affect 5-10% of the global population.
Why It Matters - MDNA209's development signals potential market opportunities in autoimmune treatments, impacting stock valuations and investor interest in biotech firms focused on innovative therapies.
Summary - Medicenna Therapeutics appointed Mr. Karim Lalji to its Board of Directors effective August 14, 2024. The company focuses on developing Superkines in immunotherapy.
Why It Matters - The appointment of Karim Lalji to Medicenna's Board may signal strategic shifts or new expertise, potentially impacting company direction and investor confidence in its growth prospects.
Summary - A melanoma patient achieved complete response after 52 weeks of MDNA11 treatment, with 100% regression of lesions, highlighting its potential as a leading therapy.
Why It Matters - The successful treatment of melanoma with MDNA11 highlights its strong efficacy, potentially positioning the company as a leader in oncology, which could drive stock value and investor interest.
Summary - Medicenna Therapeutics focuses on engineered interleukins for oncology. Key products MDNA11 and Bizaxofusp show promise in trials, but recent Nasdaq delisting poses liquidity challenges.
Why It Matters - Medicenna's clinical advancements in oncology could drive future revenue, but Nasdaq delisting raises concerns over liquidity and funding, impacting long-term viability and stock performance.